This biopharmaceutical company has witnessed three positive estimate revision in the last 30 days. The Zacks Consensus Estimate has also moved higher over the same period. This implies strong trading potential for the company. So make sure to keep an eye on this stock going forward to see if yesterday’s sharp climb can turn into more strength down the road.
Palatin currently holds a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.
Investors interested in the biomedical industry may consider better-ranked stocks like Alexion Pharmaceuticals, Inc. (ALXN), Gilead Sciences Inc. (GILD) and Actelion Ltd. (ALIOF). While ALXN and GILD sport a Zacks Rank #1 (Strong Buy), ALIOF bears a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment